Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

tag tagrisso

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

pharmaphorum

JANUARY 5, 2022

Excluded from that study are patients with EGFR mutations, and AbbVie is looking specifically at this group in a phase 1 study that is looking at the combination of Teliso-V and AstraZeneca’s EGFR inhibitor Tagrisso (osimertinib), to see if the ADC can boost efficacy and potentially reduce the risk of resistance developing.

Antibody

Antibody Drugs Protein Gene

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

DECEMBER 23, 2021

Patritumab deruxtecan achieved an overall response rate of 25% when given as a therapy to patients with EGFR-mutated NSCLC whose cancer had progressed despite treatment with a third-generation EGFR inhibitor like AstraZeneca’s Tagrisso (osimertinib) and platinum-based chemotherapy.

Drugs

Drugs Antibody Clinical Trials Clinical Trials

FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

Stay Connected